Randomized Trial: New Antibiotic Seems Effective for Community-Acquired Bacterial Pneumonia

Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Lefamulin—A New Antibiotic for Community-Acquired Pneumonia (free for a limited period)

Related Commentary on Twitter

Among patients with CABP, 5-day oral lefamulin was noninferior to 7-day oral moxifloxacin with respect to early clinical response at 96 hours after first dose https://t.co/wwQrx79kFq

— JAMA (@JAMA_current) September 28, 2019